In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cardiac Pathways raises $32mm in Series B financing

Executive Summary

Publicly traded tachyarrhythmia systems developer Cardiac Pathways raised $32mm through a private placement of 32,000 shares of Series B preferred stock, priced at $1,000 each. Each share of the Series B stock is convertible into 200 of CP's post-split common shares. The company will use proceeds for expansion of marketing and R&D programs.
Deal Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies